T
Tarek Hassanein
Researcher at University of California, San Diego
Publications - 250
Citations - 16173
Tarek Hassanein is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Ribavirin & Hepatitis C. The author has an hindex of 58, co-authored 235 publications receiving 14767 citations. Previous affiliations of Tarek Hassanein include University of California, Berkeley & Integris Baptist Medical Center.
Papers
More filters
Journal ArticleDOI
Sofosbuvir for previously untreated chronic hepatitis C infection
Eric Lawitz,Alessandra Mangia,David L. Wyles,Maribel Rodriguez-Torres,Tarek Hassanein,Stuart C. Gordon,Michael Schultz,M. Davis,Zeid Kayali,K. Rajender Reddy,Ira M. Jacobson,Kris V. Kowdley,L. Nyberg,G. Mani Subramanian,Robert H. Hyland,Sarah Arterburn,Deyuan Jiang,John McNally,Diana M. Brainard,William T. Symonds,John G. McHutchison,Aasim Sheikh,Zobair M. Younossi,Edward Gane +23 more
TL;DR: In a single-group study of sofosbuvir combined with peginterferon-ribavirin, patients with predominantly genotype 1 or 4 HCV infection had a rate of sustained virologic response of 90% at 12 weeks.
Journal ArticleDOI
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
Mark S. Sulkowski,David F. Gardiner,Maribel Rodriguez-Torres,K. Rajender Reddy,Tarek Hassanein,Ira M. Jacobson,Eric Lawitz,Anna S. Lok,Federico Hinestrosa,Paul J. Thuluvath,Howard J. Schwartz,David R. Nelson,Gregory T. Everson,Timothy Eley,Megan Wind-Rotolo,Shu-Pang Huang,Min Gao,Dennis Hernandez,Fiona McPhee,Diane Sherman,R. Hindes,William T. Symonds,Claudio Pasquinelli,Dennis M. Grasela +23 more
TL;DR: Once-daily oral daclatasvir plus sofosbuvir was associated with high rates of sustained virologic response among patients infected with HCV genotype 1, 2, or 3, including patients with no response to prior therapy with telaprevir or boceprevir.
Journal ArticleDOI
ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
Peter Ferenci,David E. Bernstein,Jacob Lalezari,Daniel E. Cohen,Yan Luo,Curtis Cooper,Edward Tam,Rui Tato Marinho,Naoky Tsai,A. Nyberg,Terry Box,Ziad Younes,Pedram Enayati,Sinikka Green,Yaacov Baruch,Bal R. Bhandari,Florin Alexandru Caruntu,Thomas Sepe,Vladimir Chulanov,Ewa Janczewska,Giuliano Rizzardini,J. Gervain,Ramon Planas,Christophe Moreno,Tarek Hassanein,Wangang Xie,M. King,Thomas Podsadecki,K. Rajender Reddy +28 more
TL;DR: Twelve weeks of treatment with ABT-450/r-ombitasvir and dasabuvir without ribavirin was associated with high rates of sustained virologic response among previously untreated patients with HCV genotype 1 infection.
Journal ArticleDOI
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.
David Roth,David R. Nelson,Annette Bruchfeld,AnnMarie Liapakis,Marcelo Silva,Howard Paul Monsour,Paul J. Martin,Stanislas Pol,Maria Carlota Londoño,Tarek Hassanein,Philippe J. Zamor,Eli Zuckerman,Shuyan Wan,Beth Jackson,Bach-Yen Nguyen,Michael N. Robertson,Eliav Barr,Janice Wahl,Wayne Greaves +18 more
TL;DR: Once-daily grazoprevir and elbasvir for 12 weeks had a low rate of adverse events and was effective in patients infected with HCV genotype 1 and stage 4-5 chronic kidney disease.
Journal ArticleDOI
Diagnostic Performance of Magnetic Resonance Elastography in Staging Liver Fibrosis: A Systematic Review and Meta-analysis of Individual Participant Data
Siddharth Singh,Sudhakar K. Venkatesh,Zhen Wang,Frank H. Miller,Utaroh Motosugi,Russell N. Low,Tarek Hassanein,Patrick Asbach,Edmund M. Godfrey,Meng Yin,Jun Chen,Andrew P. Keaveny,Mellena D. Bridges,Anneloes Bohte,Mohammad Hassan Murad,David J. Lomas,Jayant A. Talwalkar,Richard L. Ehman +17 more
TL;DR: Based on a pooled analysis of data from individual participants, MRE has a high accuracy for the diagnosis of significant or advanced fibrosis and cirrhosis, independent of BMI and etiology of CLD.